Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Furst, D., Weisman, M.H., St., C.E.W., Lipsky, P.E., Sustained Improvement Over Two Years in Physical Function, Structural Damage, and Signs and Symptoms Among Patients With Rheumatoid Arthritis Treated With and Methotrexate (2004) Arthritis and Rheumatism, 50 (4), pp. 1051-1065. , DOI 10.1002/art.20159
St.Clair, E.W., Van Der, H.D.M.F.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, P., Keystone, E., Baker, D., Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial (2004) Arthritis and Rheumatism, 50 (11), pp. 3432-3443. , DOI 10.1002/art.20568
Klareskog, L., Van Der, H.D., De Jager, J.P., Gough, A., Kalden, J., Malaise, M., Martin, M.E., Sanda, M., Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial (2004) Lancet, 363 (9410), pp. 675-681. , DOI 10.1016/S0140-6736(04)15640-7, PII S0140673604156407
Van Der, H.D., Klareskog, L., Rodriguez-Valverde, V., Codreanu, C., Bolosiu, H., Melo-Gomes, J., Tornero-Molina, J., Fatenejad, S., Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial (2006) Arthritis and Rheumatism, 54 (4), pp. 1063-1074. , DOI 10.1002/art.21655
Keystone, E.C., Kavanaugh, A.F., Sharp, J.T., Tannenbaum, H., Hua, Y., Teoh, L.S., Fischkoff, S.A., Chartash, E.K., Radiographic, Clinical, and Functional Outcomes of Treatment with Adalimumab (a Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients with Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-Controlled, 52-Week Trial (2004) Arthritis and Rheumatism, 50 (5), pp. 1400-1411. , DOI 10.1002/art.20217
Smolen, J., Landewé, R.B., Mease, P., Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial (2009) Ann Rheum Dis, 68, pp. 797-804
Galadari, H., Fuchs, B., Lebwohl, M., Newly available treatments for psoriatic arthritis (2003) Int J Dermatol, 53, pp. 231-1217
Kavanaugh, A., Antoni, C.E., Gladman, D., Wassenberg, S., Zhou, B., Beutler, A., Keenan, G., Van Der, H.D., The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year (2006) Annals of the Rheumatic Diseases, 65 (8), pp. 1038-1043. , DOI 10.1136/ard.2005.045658
Van Der, H.D., Kavanaugh, A., Gladman, D.D., Antoni, C., Krueger, G.G., Guzzo, C., Zhou, B., Beutler, A., Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2 (2007) Arthritis and Rheumatism, 56 (8), pp. 2698-2707. , DOI 10.1002/art.22805
Mease, P.J., Kivitz, A.J., Burch, F.X., Siegel, E.L., Cohen, S.B., Ory, P., Salonen, D., Tsuji, W., Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression (2004) Arthritis and Rheumatism, 50 (7), pp. 2264-2272. , DOI 10.1002/art.20335
Mease, P.J., Gladman, D.D., Ritchlin, C.T., Ruderman, E.M., Steinfeld, S.D., Choy, E.H.S., Sharp, J.T., Weinberg, M.A., Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial (2005) Arthritis and Rheumatism, 52 (10), pp. 3279-3289. , DOI 10.1002/art.21306
Van Der Heijde, D., Dijkmans, B., Geusens, P., Effi≠cacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT) (2005) Arthritis Rheum, 52, pp. 582-590
McLeod, C., Bagust, A., Boland, A., Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation (2007) Health Technol Assess, 11, pp. 1-158
Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sorensen, H., Grassnickel, L., Rudwaleit, M., Braun, J., Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis (2003) Arthritis and Rheumatism, 48 (6), pp. 1667-1675. , DOI 10.1002/art.11017
Boyce, E.G., Halilovic, J., Stan-Ugbene, O., Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor (2010) Clin Ther, 32, pp. 1681-1703
Giannini, E.H., Ilowite, N.T., Lovell, D.J., Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis (2009) Arthritis Rheum, 60, pp. 2794-2804
Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., Sibilia, J., Prieur, A.-M., Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type (2003) Arthritis and Rheumatism, 48 (4), pp. 1093-1101. , DOI 10.1002/art.10885
Lovell, D.J., Ruperto, N., Goodman, S., Adalimumab with or without methotrexate in juvenile rheumatoid arthritis (2008) N Engl J Med, 359, pp. 810-820
Ter Wee, M.M., Lems, W.F., Usan, H., The effect of biological agents on work participation in rheumatoid arthritis patients: A systematic review (2012) Ann Rheum Dis, 71, pp. 161-171
Van Der, H.D., Landewe, R., Einstein, S., Ory, P., Vosse, D., Ni, L., Lin, S.-L., Davis Jr., J.C., Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept (2008) Arthritis and Rheumatism, 58 (5), pp. 1324-1331. , DOI 10.1002/art.23471
Van Der Heijde, D., Landewé, R., Baraliakos, X., Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis (2008) Arthritis Rheum, 58, pp. 3063-3070
Etanercept plus standard therapy for Wegener's granulomatosis (2005) N Engl J Med, 27, pp. 351-361. , Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
Jones, G., Sebba, A., Gu, J., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study (2010) Ann Rheum Dis, 69, pp. 88-96
Emery, P., Keystone, E., Tony, H.P., IL-6 receptor inhibition with tocilizumab improves treatment outco≠mes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial (2008) Ann Rheum Dis, 67, pp. 1516-1523
Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Murata, N., Kishimoto, T., Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab (2007) Annals of the Rheumatic Diseases, 66 (9), pp. 1162-1167. , DOI 10.1136/ard.2006.068064
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Kishimoto, T., Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial (2008) The Lancet, 371 (9617), pp. 998-1006. , DOI 10.1016/S0140-6736(08)60454-7, PII S0140673608604547
Cohen, S.B., Moreland, L.W., Cush, J.J., Greenwald, M.W., Block, S., Shergy, W.J., Hanrahan, P.S., Bear, M.B., A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate (2004) Annals of the Rheumatic Diseases, 63 (9), pp. 1062-1068. , DOI 10.1136/ard.2003.016014
Koné-Paut, I., Lachmann, H.J., Kuemmerle-Deschner, J.B., Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: Results of a double-blind placebo-controlled randomized withdrawal study (2011) Arthritis Res Ther, p. 13. , Epub ahead of print
Hoffman, H.M., Throne, M.L., Amar, N.J., Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies (2008) Arthritis Rheum, 58, pp. 2443-2452
Kingsbury, S.R., Conaghan, P.G., McDermott, M.F., The role of the NLRP3 inflammasome in gout (2011) J Inflamm Res, 4, pp. 39-49
Schlesinger, N., Mysler, E., Lin, H.Y., Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study (2011) Ann Rheum Dis, 70, pp. 1264-1271
Schumacher Jr., H.R., Sundy, J.S., Terkeltaub, R., Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a Phase 2 clinical trial (2012) Arthritis Rheum, 64, pp. 876-884
Burns, C.M., Wortmann, R.L., Gout therapeutics: New drugs for an old disease (2011) Lancet, 377, pp. 165-177
Navarra, S.V., Guzmán, R.M., Gallacher, A.E., Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial (2011) Lancet, 377, pp. 721-731
Furie, R., Petri, M., Zamani, O., A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus (2011) Arthritis Rheum, 63, pp. 3918-3930
